The biotech sector is entering 2026 with a positive outlook, characterized by reasonable valuations, robust oncology momentum and supportive policy…
Correction: The conversion price was incorrectly reported as .14/share. The correct price is .165/share Correction: Nextech3D.ai Provides Shareholder Update on…
Craig Hemke, publisher of TFMetalsReport.com, shares his thoughts on the gold and silver markets heading into 2026, outlining why he…